Revvity, Inc. (NYSE: RVTY), a global leader in health science solutions, has strengthened its partnership with Genomics England to advance groundbreaking genomic research across the United Kingdom. The collaboration, which builds on years of joint efforts, aims to enhance early diagnosis and intervention for rare genetic conditions, transform genomic healthcare, and foster innovative talent in clinical-grade genomics.

At the heart of this partnership is the Generation Study, a pioneering initiative by Genomics England in collaboration with the National Health Service (NHS). The study is poised to screen up to 100,000 newborns for over 200 rare genetic conditions, setting a new standard in early genetic screening. Revvity’s state-of-the-art Omics laboratory in Manchester, UK, plays a critical role, leveraging its cutting-edge chemagic 360 instrument to extract DNA from cord blood samples collected from newborns across England.

Dr. Madhuri Hegde, senior vice president and chief scientific officer at Revvity, expressed enthusiasm for the expanded partnership, emphasizing its potential to save lives by enabling earlier detection of rare conditions. She also highlighted the significance of selecting Manchester as the hub for this initiative, underlining the company’s commitment to nurturing talent in molecular genomics and advancing regional expertise.

Genomics England, known for spearheading the transformative 100,000 Genomes Project, continues its mission to integrate genomic medicine into routine clinical care. The organization’s chief medical officer, Dr. Ellen Thomas, noted that combining Genomics England’s research strengths with Revvity’s laboratory expertise will drive significant advancements in genomics, paving the way for earlier diagnoses and innovative healthcare solutions.

This collaboration arrives at a pivotal moment for genomic medicine, with increasing recognition of the role of early screening in improving healthcare outcomes. By enabling large-scale genetic screening for newborns, the partnership has the potential to redefine how rare genetic disorders are detected and managed, offering hope to families affected by these conditions.

Revvity, a member of the S&P 500 index, serves customers in over 190 countries and reported revenue exceeding $2.7 billion in 2023. Its broad expertise spans translational multi-omics technologies, biomarker discovery, imaging, diagnostics, and informatics. Genomics England complements this expertise by supporting the NHS’s whole genome sequencing service and maintaining the National Genomic Research Library, which advances genomic research and clinical care integration.

The Generation Study is not only a testament to the progress in genomic medicine but also a model for future collaborations in healthcare innovation. By uniting industry leaders, research institutions, and government agencies, the partnership between Revvity and Genomics England represents a critical step toward a future where genomic healthcare is accessible and transformative for all.

  Generation Study, Genomics England, NHS, Revvity